Cemiplimab (REGN2810), a Fully Human Anti-PD-1 Monoclonal Antibody, for Patients with Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: Initial Safety and Efficacy from Expansion Cohorts of Phase 1 Study. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 2, n. S1, p. S45, 2018. DOI: 10.25251/skin.2.supp.45. Disponível em: https://skin.dermsquared.com/skin/article/view/301. Acesso em: 19 apr. 2025.